News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
NxStage Medical, Inc. Cuts Expected IPO Price Range
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Oct 26 (Reuters) - Medical device company NxStage Medical Inc. cut the expected price for its initial public offering to between $11 and $12 a share from a previous range of $13 to $15, according to a regulatory filing on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
IPO tracker
Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic
April 9, 2026
·
7 min read
·
Tristan Manalac
Deals
Roche sticks with C4T, adding up to $1B for molecular glue partnership
April 9, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data
April 8, 2026
·
3 min read
·
Tristan Manalac
Podcast
Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
April 8, 2026
·
1 min read
·
Heather McKenzie
